Key Takeaways
- India engine firing, rank jumps 9 places: Domestic business grew 30%, moving from 32nd to 23rd in the IPM, powered by legacy brand strength, a realigned go-to-market model, and new therapy entries.
- Chronic shift accelerates toward 50%: The chronic portfolio contribution moved from 40% to close to 50%, driven by hypertension, GI, nephrology, and the Sanzyme acquisition, with a stated target of 55%.
- Sanzyme and Azmarda are the twin bets: The ₹650 Cr Sanzyme acquisition adds a probiotics platform to double market share, while the in-licensed Azmarda (heart failure) is being positioned for a volume surge post patent expiry.
- Margins held at ~25% despite cost headwinds: Gross margins stayed near 65% for the full year through pricing and cost initiatives, and operating EBITDA is guided at 24–26% for the next year, contingent on cost standstill assumptions.
- What to watch next quarter: The pace of Sanzyme integration and revenue contribution, Azmarda’s prescription spread in its 6–8 month pre-LOE window, and whether CMO demand sustains the Q4 bounce-back.
India Business Transformation
- Rank climb: The company jumped from 32nd to 23rd in the IPM, a climb management called unprecedented in Indian pharma history, driven by big brands getting bigger and a new go-to-market strategy.
- Organic growth beat the market: Organic India growth (excluding Sanzyme) was 20% plus, double the IPM growth of 10%, showing the core franchise is accelerating independently of acquisitions.
- Prescriber productivity, not headcount: The field force was optimized from ~900 to ~600 people in combined Rantac and Metrogyl units, freeing 300 people to launch a new pediatrics and respiratory division with zero net manpower addition and no intention to add any for 18–24 months.
- Per person productivity improved from ~₹3.5 lakhs in FY2019 to ~₹5.6 lakhs currently, with a target of ₹6–8 lakhs and an identified opportunity to add ₹1.5–2 lakhs in lower-productivity geographies over 18–24 months.
- Specialist mix rising: The contribution from cardiologists, nephrologists, respiratory specialists, and pediatricians will increase, particularly in metro and tier-1 towns, as the portfolio shifts toward chronic and progressive SKUs.
- New products scaling: New product contribution rose from 1.5% to 4% of revenue; 17 new products were launched in pediatrics, respiratory, metabolic, and cardiology, with half a dozen expected to generate ₹12–14 Cr each, totaling ~₹100 Cr in 18–24 months.
Chopra: "this have never happened in the history of Indian pharma market and if it has to happen I think J.B. will be the only company to climb more ranks"
Sanzyme & Azmarda: The Two Big Bets
Sanzyme (Probiotics)
- Acquisition rationale: Acquired for ₹650 Cr, adding ~₹150 Cr in revenue and brands Sporlac, Lobun, and Oxalo, making J.B. the fifth-largest probiotic company with intent to reach the top three.
- Growth ambition: The acquired asset was growing at 8–9%; management wants to lift it to 15–16% by leveraging J.B.’s geographic presence in UP, Bengal, and Kerala where Sanzyme is underpenetrated.
- Line extensions planned: A liquid probiotic formulation is in development; Sporlac sachets and tablets are being readied to widen the franchise.
- Financial aspiration: Management expects to do better than the historic ~₹230 Cr revenue with 28–29% EBITDA margin, targeting ₹100 Cr profit in 3–4 years, implying a 15–16% return on the acquisition.
- FY22 contribution was negligible as only the first two months of operation were in the books, focused on integration.
Kataria: “...suppose we are making say 50 Crores to 60 Crores today with 600 Crores sort of acquisition so three or four years down the line if this business starts making 100 Crores we are already making 15% to 16%, treasuries are not going to give you 15% to 16% even three years down the line...”
Azmarda (Heart Failure)
- Pre-LOE positioning: In-licensed from Novartis (Sacubitril/Valsartan), the molecule goes off patent in November–December; the 6–8 month window is being used to build medical marketing presence and spread prescriptions among cardiologists.
- Post-LOE volume expectation: Management cited precedents like Ticagrelor and Vildagliptin where volumes went up three times post patent expiry, neutralizing price impact; Azmarda volumes are expected to go up 2–2.5x within two to three years.
- Margin accretion post-LOE: Currently importing the drug under the Novartis arrangement with a limited gross margin profile; post-LOE, domestic and localized sourcing will significantly improve gross margins and neutralize any price impact.
- Specialist access unlocked: The Azmarda engagement brought 70 top cardiologists, diabetologists, and nephrologists to J.B. meetings, opening doors in hypertension and heart failure that the company did not previously have.
Khanna: "Going forward certainly the competition is going to intensify... however, having said that if you see what has happened in the Indian market over the last four years whenever a molecule has gone off patent... in most cases the volumes have actually gone up three times, which have actually helped to neutralize any price impact..."
Portfolio & Therapy Expansion
- Chronic shift: Chronic contribution moved from 40% to close to 50%, with a target of 55%, driven by work in hypertension, GI, nephrology, and the Sanzyme addition.
- New therapy entries: Ventured into pediatrics, respiratory, metabolic, and diuretics through new launches and a dedicated new division, staffed by people freed from Rantac and Metrogyl optimization.
- Cilacar franchise ambition: The flagship brand, spanning 50 SKUs, has an aspiration to reach ₹1,000 Cr in the next five years through incremental innovation and line extensions.
- Legacy brand resilience: Metrogyl continues to deliver market-beating growth; topical preparations (ANO-Metrogyl, Metrogyl P, Metrogyl gel) provide non-seasonal growth, while oral and IV forms are more seasonally dependent.
- Trade generics limited: Less than 5% of the portfolio (cough and cold, pain, legacy non-prescription products) has been shifted into trade generics; management sees enough opportunity in acquired assets and new launches to not make this meaningful in the near term.
- Respiratory strategy selective: Will not enter inhalation; focusing on selective opportunities in lung fibrosis, pulmonary hypertension, mucolytic agents, and antiallergics, with prescription traction building though revenues are not yet at scale after a six-month journey.
Chopra: "actually friends it is not a five brand, we are talking of 50 SKUs put together in this franchises"
International & CMO Business
- International bounce-back: The international business delivered low double-digit growth in Q4, supported by BGS geographies and South Africa growing at 20% plus against a single-digit market.
- South Africa scale-up: Now a 50-brand company in South Africa, looking to increase private market contribution; one or two M&A opportunities are being evaluated as a generic play.
- Russia/CIS guarded approach: Demand has been steady over the last 2–3 months since the war confrontation started; receivables have shown progressive traction and the company is adequately hedged. Management will continue to supply medicines but takes a guarded approach; mid-to-long term opportunity exists but is too early to call.
- CMO demand recovery: Q2 and Q3 were weak, but Q4 saw demand coming back from a big partner; standalone Q4 figures were uphill and not the run rate going ahead, but a robust order book is seen for the coming year from Southeast Asia, Russia, Canada, Australia, and New Zealand.
- CMO ambition: Currently a ~$30 million business, targeting 15–20% revenue contribution in 3–5 years, looking to double and triple it by expanding beyond cough and cold into immunity, wellness, and GI disorders.
- Lozenges expansion: Launched Lozenges with Aquazyl for dry mouth and Sensi Cool Lozenges in India; Reckitt added as the latest CMO partner; half a dozen proof-of-concept products available and under stability, with half a dozen more products coming in India across prescription and OTC.
Chopra: "We have the capability, we have the capacity, we know how in terms of the relationship that we enjoy with all the big players so why Indian population, Indian patients should be denied with world class Lozenges that today many of the consumers globally have been consuming from the house of J.B."
US Strategy: Guarded & Selective
- Cost-plus model: The US business operates on a cost-plus model, not directly present in the market; the company holds 15 ANDAs, some with backward integration of APIs manufactured in-house.
- Filing ambition: Plans to file 8–10 ANDAs in the next couple of years, targeting low-volume, high-value, niche-competition products with API backward integration for cost competitiveness.
- Not chasing scale: Management explicitly stated it does not want to become a $200–300 million US business where price erosion pressure intensifies; the strategy is to test selective opportunities in ORS technology and laser technology.
- RoW leverage separate: ANDA approvals are leveraged across Middle East and Asia-PAC for faster approvals, but the US strategy is not centered on getting faster RoW access; a different portfolio is being developed for RoW markets.
- Investment rationale questioned: An analyst asked why it makes sense to continue US investment given competitive intensity and persistent price erosion; management responded with the cost-plus model, selective approach, and guarded and conservative framing.
Kataria: "I think as far as US is concerned so far the only thing we will maintain is the success is being extremely guarded and conservative right, that is the major difference between us and some of our peers..."
Margins, Costs & Capital Allocation
- Gross margin resilience: Held close to 64–65% across quarters and closer to 65% for the full year despite cost pressures from freight, raw materials, packing materials, and power and fuel catching up across the industry. Managed through a mix of pricing, cost initiatives, and efficiency projects.
- Strategic sourcing delayed cost impact: The operations team hedged against cost headwinds through strategic sourcing and long-term contracts, which delayed some cost increases into future quarters.
- Q4 underlying margin ~25.5%: Reported operating EBITDA was supported by very strong CMO performance with ₹85 Cr revenue in Q4.
- PAT did not show full EBITDA fall-through because one-offs of about ₹40–50 Cr from the prior year went away and treasury income reduced as cash was invested for growth and acquisitions.
- Working capital investment: Reported cash from operations of ~₹170 Cr does not reflect real business performance because ~₹300 Cr was invested in working capital, largely attributable to brand acquisition GST payments and conscious supply-chain investments (advances, inventories, trade receivables) to ensure business continuity.
- Capital allocation domestic-first: 70% of time, investment, bandwidth, and capital allocation is going to further the domestic franchise.
- M&A discipline: Will continue to evaluate synergistic assets in present therapies but will not chase mad valuations or put unnecessary stress on the balance sheet; may look at buying dossiers from multinational companies for geographies where present.
- Rebranding completed: The company unveiled a new identity, "J.B. Good People for Good Health," and confirmed no royalty is paid after rebranding, versus around 1% of sales previously.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| India IPM rank | Enter top 20 companies | No date given |
| Domestic revenue contribution | Increase from 50% to 60% of total business | No date given |
| Chronic portfolio contribution | Increase to 55% | No date given |
| Cilacar franchise revenue | Reach ₹1,000 Cr | Next 5 years |
| New product revenue | Half a dozen products generating ₹12–14 Cr each, totaling ~₹100 Cr | Next 18–24 months |
| Per person productivity | Reach ₹6–8 lakhs (from ~₹5.6 lakhs) | No date given |
| MR productivity uplift | Add ₹1.5–2 lakhs in lower-productivity geographies | 18–24 months |
| Manpower addition | Zero net addition to field force | Next 18–24 months |
| Sanzyme probiotic ranking | Become top 3 player (from 5th) | No date given |
| Sanzyme profit | ₹100 Cr profit, implying 15–16% return on acquisition | 3–4 years |
| Sporlac brand rank | Enter top 300 brands | Next 8–10 months |
| Azmarda brand rank | Enter top 300 brands | Next 8–12 months |
| Azmarda post-LOE volumes | Go up 2–2.5x | 2–3 years post LOE (LOE: Nov–Dec 2022) |
| Operating EBITDA margin | 24% to 26% range | Next one year (FY23) |
| US ANDA filings | File 8–10 ANDAs (low volume, high value, niche) | Next couple of years |
| CMO revenue contribution | Reach 15–20% of total revenue | 3–5 years |
| CMO business scale | Double and triple the current ~$30 million business | 3–5 years |
| Sanzyme revenue growth | Lift from 8–9% to 15–16% | "Coming time" (no specific date) |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Revenue | ₹625 cr, +18% YoY |
| FY22 revenue | ₹2,400 cr, +19% YoY, ₹400 cr addition |
| India business growth | 30% |
| International business growth | Low double-digit |
| Adjusted EBITDA | ₹164 cr, +32% YoY (₹124 cr in Q4 FY21) |
| Adjusted EBITDA margin | 25.5% to 26% |
| FY22 adjusted EBITDA | ₹634 cr, +13% YoY (₹560 cr in FY21) |
| FY22 gross margin | Closer to 65% |
| FY22 PAT (reported) | ₹386 cr |
| FY22 tax rate | Closer to 25%; Q4 lower due to mutual fund sales |
| India business rank | 23rd, up from 32nd in Oct 2020 |
| India business market share | Close to 1% |
| Chronic portfolio contribution | Close to 50%, up from 40% in FY2018-19 |
| New product contribution | 4%, up from 1.5% |
| MR count | 2,500 across all three entities |
| Per person productivity (India) | ~₹5.6 lakhs, up from ~₹3.5 lakhs in FY2019 |
| Sanzyme acquisition cost | ₹650 cr |
| Sanzyme acquired revenue | ₹140 cr, gross margin 70%+ |
| Sanzyme market share (probiotics) | 7.5%, fifth largest player |
| Cilacar franchise | ₹300 cr |
| South Africa business | Close to ₹300 cr, 100% subsidiary |
| Russia business | ~$20 million |
| US business | Close to $30 million, 15 ANDAs |
| Cash from operations (FY22) | ~₹170 cr |
| Cash generated (FY22) | ~₹30 cr |
| FY23 EBITDA margin guidance | 24% to 26% |
| NPP portfolio (% of domestic revenue) | 25% to 30% |